Jazz Pharmaceuticals plc Other Comprehensive Income (Loss), Net of Tax
Jazz Pharmaceuticals plc (JAZZ) reported Other Comprehensive Income (Loss), Net of Tax of -$266.01 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-03-01
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for the quarter ending 2019-06-30 was $10.24M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for the quarter ending 2019-03-31 was -$22.88M, a 154.41% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for the quarter ending 2018-06-30 was -$69.46M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for the quarter ending 2018-03-31 was $42.06M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for fiscal 2021 was -$266.01M, a 398.75% decline from fiscal 2020.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for fiscal 2020 was $89.04M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for fiscal 2019 was -$25.60M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax for fiscal 2018 was -$56.97M, a 132.28% decline from fiscal 2017.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$266.01M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $89.04M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | -$25.60M 10-K · filed 2022-03-01 | |||
| 2019-06-30 | $10.24M 10-Q · filed 2019-08-06 | -$12.64M derived: sum of 2 quarters · filed 2019-08-06 | ||
| 2019-03-31 | -$22.88M 10-Q · filed 2019-08-06 | |||
| 2018-12-31 | -$56.97M 10-K · filed 2021-02-23 | |||
| 2018-06-30 | -$69.46M 10-Q · filed 2019-08-06 | -$27.40M derived: sum of 2 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $42.06M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $176.46M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | -$81.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$67.34M derived: sum of 2 quarters · filed 2019-02-26 | -$95.05M derived: sum of 3 quarters · filed 2019-02-26 | -$49.86M 10-K · filed 2019-02-26 |
| 2016-09-30 | $14.61M 10-Q · filed 2016-11-08 | -$13.09M derived: sum of 2 quarters · filed 2016-11-08 | $32.10M 10-Q · filed 2016-11-08 | -$4.11M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$27.70M 10-Q · filed 2016-08-09 | $17.48M 10-Q · filed 2016-08-09 | -$18.72M derived: sum of 3 quarters · filed 2018-02-27 | -$1.94M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $45.19M 10-Q · filed 2016-05-10 | $8.99M derived: sum of 2 quarters · filed 2018-02-27 | $25.77M derived: sum of 3 quarters · filed 2018-02-27 | $56.31M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$36.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$19.42M derived: sum of 2 quarters · filed 2018-02-27 | $11.12M derived: sum of 3 quarters · filed 2018-02-27 | -$145.38M 10-K · filed 2018-02-27 |
| 2015-09-30 | $16.78M 10-Q · filed 2016-11-08 | $47.32M derived: sum of 2 quarters · filed 2016-11-08 | -$109.17M 10-Q · filed 2016-11-08 | -$174.15M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $30.54M 10-Q · filed 2016-08-09 | -$125.95M 10-Q · filed 2016-08-09 | -$190.92M derived: sum of 3 quarters · filed 2017-02-28 | -$308.01M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | -$156.50M 10-Q · filed 2016-05-10 | -$221.47M derived: sum of 2 quarters · filed 2017-02-28 | -$338.56M derived: sum of 3 quarters · filed 2017-02-28 | -$349.78M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | -$64.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$182.06M derived: sum of 2 quarters · filed 2017-02-28 | -$193.28M derived: sum of 3 quarters · filed 2017-02-28 | -$178.26M 10-K · filed 2017-02-28 |
| 2014-09-30 | -$117.09M 10-Q · filed 2015-11-09 | -$128.31M derived: sum of 2 quarters · filed 2015-11-09 | -$113.29M 10-Q · filed 2015-11-09 | -$101.76M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-06-30 | -$11.22M 10-Q · filed 2015-08-05 | $3.80M 10-Q · filed 2015-08-05 | $15.33M derived: sum of 3 quarters · filed 2016-02-23 | $40.73M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-03-31 | $15.02M 10-Q · filed 2015-05-07 | $26.55M derived: sum of 2 quarters · filed 2016-02-23 | $51.95M derived: sum of 3 quarters · filed 2016-02-23 | $60.56M derived: sum of 4 quarters · filed 2016-02-23 |
| 2013-12-31 | $11.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $36.93M derived: sum of 2 quarters · filed 2016-02-23 | $45.55M derived: sum of 3 quarters · filed 2016-02-23 | $25.11M 10-K · filed 2016-02-23 |
| 2013-09-30 | $25.40M 10-Q · filed 2014-11-04 | $34.02M derived: sum of 2 quarters · filed 2014-11-04 | $13.58M 10-Q · filed 2014-11-04 | $30.76M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $8.61M 10-Q · filed 2014-08-05 | -$11.83M 10-Q · filed 2014-08-05 | $5.36M derived: sum of 3 quarters · filed 2015-02-24 | $19.61M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$20.44M 10-Q · filed 2014-05-08 | -$3.25M derived: sum of 2 quarters · filed 2015-02-24 | $10.99M derived: sum of 3 quarters · filed 2015-02-24 | $10.60M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $17.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $31.43M derived: sum of 2 quarters · filed 2015-02-24 | $31.04M derived: sum of 3 quarters · filed 2015-02-24 | $31.08M 10-K · filed 2015-02-24 |
| 2012-09-30 | $14.25M 10-Q · filed 2013-11-05 | $13.86M derived: sum of 2 quarters · filed 2013-11-05 | $13.89M 10-Q · filed 2013-11-05 | $13.86M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$391.00K 10-Q · filed 2013-08-06 | -$357.00K 10-Q · filed 2013-08-06 | -$386.00K derived: sum of 3 quarters · filed 2014-02-25 | -$388.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $34.00K 10-Q · filed 2013-05-07 | $5.00K derived: sum of 2 quarters · filed 2014-02-25 | $3.00K derived: sum of 3 quarters · filed 2014-02-25 | |
| 2011-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$31.00K derived: sum of 2 quarters · filed 2014-02-25 | -$31.00K 10-K · filed 2014-02-25 | |
| 2011-09-30 | -$2.00K 10-Q · filed 2012-11-09 | -$2.00K 10-Q · filed 2012-11-09 | ||
| 2010-12-31 | $0.00 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |